4 May 2022 - Approval for relapsed or refractory follicular lymphoma is the third indication for Kymriah in the EU
Novartis announced today that the European Commission has approved Kymriah (tisagenlecleucel), a CAR-T cell therapy, for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.